



OPEN

Repurposing CPAP machines as stripped-down ventilators

J. Nguyen¹✉, K. Kesper², G. Kräling³, C. Birk¹, P. Mross⁴, N. Hofeditz¹, J. Höchst⁵, P. Lampe⁵, A. Penning⁵, B. Leutenecker-Twelsiek⁶, C. Schindler¹, H. Buchenauer⁷, D. Geisel¹, C. Sommer¹, R. Henning⁸, P. Wallot⁸, T. Wiesmann⁸, B. Beutel⁹, G. Schneider⁷, E. Castro-Camus¹⁰ & M. Koch¹

The worldwide shortage of medical-grade ventilators is a well-known issue, that has become one of the central topics during the COVID-19 pandemic. Given that these machines are expensive and have long lead times, one approach is to vacate them for patients in critical conditions while patients with mild to moderate symptoms are treated with stripped-down ventilators. We propose a mass-producible solution that can create such ventilators with minimum effort. The central part is a module that can be attached to CPAP machines and repurpose them as low-pressure ventilators. Here, we describe the concept and first measurements which underline the potential of our solution. Our approach may serve as a starting point for open-access ventilator technologies.

The COVID-19 pandemic plunged many countries, such as Italy, Spain and the United States, into a health crisis due to the sudden demand for medical facilities, staff and equipment^{1,2}. Since the global vaccination process is still ongoing, treatments revolve around symptom control and life-sustaining measurements. Patients with COVID-19-related respiratory failures often require prolonged mechanical ventilation^{3–5}. Such a treatment, however, cannot be provided due to a long-term worldwide issue: the shortage of medical-grade ventilators^{6,7}. These costly devices have long lead times because of their complexity. Consequently, this shortage may continue to be one of few central issues during subsequent waves of the disease.

In response to the urgent need for ventilators, many designs were proposed to serve as life-sustaining measurements or to vacate medical-grade ventilators for patients in critical conditions⁸. The lead time for each proposed design depends on the range of functionalities, cost and, more importantly, the available production facilities. One prominent approach focuses on machines that automatically compress and decompress bag valve masks^{9–13}. Other groups pursue ventilator solutions that can be built from scratch with the expertise and the facilities from different industrial branches^{14–16}.

In the presence of these developments, we propose a mass-producible solution that is built around continuous positive airway pressure (CPAP) machines. These home-level ventilators are commonly used to treat sleep apnea worldwide. Nowadays, many machines sit unused in households^{17–19} and thus, there are potentially millions of CPAP machines around the globe that can be repurposed as stripped-down ventilators.

CPAP machines generate and maintain a constant positive airway pressure to the patient. To cover the fundamental functions for mechanical ventilation, however, we need to:

- provide two well-defined airway pressure levels, i.e. the peak inspiratory pressure (P_{IP}) and the positive end-expiratory pressure (PEEP), to assist or replace the patient's breathing during the inhalation and exhalation phase,
- set the respiratory rate in units of breaths per minute (bpm),
- set the I:E ratio, which is the ratio of the inhalation and the exhalation time, and
- allow patients to trigger and to cycle inhalation.

¹Faculty of Physics and Material Sciences Centre, Philipps-Universität Marburg, Marburg, Germany. ²Department of Pneumology, Philipps-Universität Marburg, Marburg, Germany. ³Department of Medical Technology, Universitätsklinikum Gießen und Marburg, Marburg, Germany. ⁴Department of Neurology, Universitätsklinikum Gießen und Marburg, Marburg, Germany. ⁵Faculty of Mathematics and Computer Science, Philipps-Universität Marburg, Marburg, Germany. ⁶TRUMPF, Ditzingen, Germany. ⁷Schneider GmbH & Co KG, Fronhausen, Germany. ⁸Department of Anaesthesiology & Intensive Care Medicine, Universitätsklinikum Gießen und Marburg, Marburg, Germany. ⁹Department of Medicine, Pulmonary and Critical Care Medicine, Universitätsklinikum Gießen und Marburg, Member of the German Centre for Lung Research (DZL), Marburg, Germany. ¹⁰Centro de Investigaciones en Óptica, A.C., Loma del Bosque 115, Lomas del Campestre, 37150 Leon, Guanajuato, Mexico. ✉email: johnny.nguyen@physik.uni-marburg.de




Figure 1. Plots of the airway pressure, flow, ventilation volume as a function of time for the P_{IP} values **(a)** $20\text{ cmH}_2\text{O}$ and **(b)** $15\text{ cmH}_2\text{O}$. Each curve corresponds to a ventilator with a different CPAP machine model (referred to as u1, u2, u3, u4 and u5). All measurements are performed on an artificial lung. Respiratory rate: 20 bpm, I:E ratio: 1:2.

Therefore, ventilation by means of CPAP machines requires a modification that regulates the constant pressure with time. We developed a module, referred to as CARL (for CPAP Apparatus Respiratory Life support), that can be attached to any CPAP machine and instantaneously repurpose it as a basic ventilator with minimum effort. We believe that our proposed solution can be used to treat patients with mild symptoms that do not require high-level pressures provided by medical-grade ventilators or to wean off recovering patients from the ventilator. We would like to clarify that the ventilator presented in this report:

- has only been tested with electric and mechanic equipment,
- is subject to pre-/clinical trials and approval, and
- has yet to be examined and approved by a regulatory health institution.

Therefore, at this stage of development, we strongly discourage the use of our device on humans. Our module should only be reproduced for the purpose of further development and investigation.

Results

CARL is an electronic device that is placed in the ventilation pathway between the CPAP machine and the patient. It uses a microcontroller-activated valve to generate two airway pressure levels from the constant pressure provided by the CPAP machine. The computer assures that the periodic alteration between both pressure levels corresponds to a set respiratory rate and I:E ratio. CARL uses pressure sensors to monitor the airway pressure, the flow, and the ventilation volume. That way, users can easily adjust the ventilator settings to the needs of the patient which is comparable to adjustments with medical-grade ventilators.

In the following, we present measurements of the airway pressure, flow, and ventilation volume (referred to as ventilation curves) for different ventilation parameters. As a representative patient model, we use an artificial lung (details in ‘Methods’).

Pressure-related ventilation settings. In our ventilator solution, the pressure is built up and maintained by a CPAP machine. Since each machine has its own feedback control system, the ventilation performance may vary with the machine model. To shed light on this, we test CARL with five different CPAP machine models while setting the P_{IP} value, respiratory rate, and I:E ratio to $20\text{ cmH}_2\text{O}$, 20 bpm and 1:2, respectively. The ventilation curves for each ventilator are presented in Fig. 1a. A comparison of the curve profiles between the ventilators reveals minor differences. This shows that each selected machine can quickly adapt to sudden pressure changes that are caused by CARL. We also see that the pressure in the plateau region depends on the selected CPAP machine: for four out of five machines, the plateau pressure stabilises around the set P_{IP} value, while for machine u5 the plateau pressure approaches $19.4\text{ cmH}_2\text{O}$. The latter observation is due to a less powerful motor compared to the other machines. On the other hand, each ventilator can keep the PEEP value above $5\text{ cmH}_2\text{O}$ which aligns with ventilation strategies for COVID-19-patients where a minimum airway pressure of at least $5\text{ cmH}_2\text{O}$ must be maintained during the exhalation phase to stabilise the alveoli^{5,20–23}.

To investigate the impact of different P_{IP} values, we repeated the same measurements but changed the P_{IP} value to $15\text{ cmH}_2\text{O}$. The ventilation curves are presented in Fig. 1b. Here, we make the same observation as before with




Figure 2. Plots of the airway pressure, flow, ventilation volume as a function of time. **(a)** Ventilation data plots acquired for the I:E ratios 1:1 and 1:2 while the respiratory rate and the P_{IP} value are set to 20 bpm and 20 cmH₂O, respectively. **(b)** Ventilation data plots acquired for the respiratory rates 16 bpm, 20 bpm and 26 bpm while the I:E ratio is 1:2 and the P_{IP} value is 20 cmH₂O. All measurements are conducted on an artificial lung and the pressure is generated with the CPAP machine u1 (see Table 3).

the difference that the plateau pressure and the PEEP value are reduced. Note, that for this case the PEEP value is below 5 cmH₂O which could be increased by adjusting CARL's design.

Both measurements demonstrate that our CARL-based ventilator can generate two pressure levels to produce ventilation patterns typical for mechanical ventilation²⁴. The acquired ventilation curves are comparable to the ones produced by already published mechanical ventilator solutions^{9–16} that vary with different sets of functionalities.

Time-related ventilation settings. Time-related ventilation settings, i.e. the respiratory rate and the I:E ratio, are adjusted on CARL. In the following, we only consider the ventilation data taken with the machine u1 (prisma SOFT, Löwenstein Medical GmbH & Co. KG), since Fig. 1a,b show that the ventilation performances between the CPAP machine models are similar.

In our first test, we vary the I:E ratio while fixing the P_{IP} value and the respiratory rate. The acquired data for the airway pressure, flow, and volume as a function of time are presented in Fig. 2a. An evaluation of the inhalation and exhalation durations confirms the correct implementation of the I:E ratios with CARL. In the volume curve for the I:E ratio setting 1:1 (solid, green), we observe that the volume is always above zero (e.g. around 3 s) due to the short duration of the exhalation phase. This residual volume can lead to a hyperinflation of the patient's lung, which must be reviewed by a trained staff member and can be beneficial depending on the patient's condition^{25,26}. Next, we vary the respiratory rate while keeping the P_{IP} value and the I:E ratio fixed. The ventilation curves are presented in Fig. 2b, where we observe an increase of the maximum ventilation volume as the respiratory rate decreases. This is expected since the duration of the inhalation phase decreases as the respiratory rate increases. We found that the respiratory rate agrees with the value that is set on CARL throughout the measurement.

Both tests also show that the plateau pressure and the PEEP do not depend on the respiratory rate and the I:E ratio. This supports our previous finding that CPAP machines can quickly adapt to the sudden pressure and flow changes induced by CARL. Similar to other ventilation solutions, both ventilation parameters can be easily implemented in the code for the internal computer^{9–16}. As such, it should be possible to cover any range of values for the respiratory rate and the I:E ratio that are outlined in international standards^{27,28} or guidelines²⁰.

Patient-triggered/patient-cycled ventilation. Patients who receive no sedation may breathe spontaneously during ventilation^{29,30}. To support such events, the ventilator must be able to recognise the patient's breathing effort, so that they can trigger and/or cycle the inspiration phase themselves. Our implementation relies on airflow monitoring which has also been implemented in another ventilation solution¹². The ventilation curves in the case of spontaneous breathing during ventilation are presented in Fig. 3. Here, the start of the inhalation and exhalation phase is marked as 'o' and 'x', respectively. When no breathing effort is detected, e.g. when the patient's breathing ceases, the ventilation is provided by the parameters set on CARL.

Long-term testing. Depending on the patient's health condition, ventilators must operate for a few days to weeks straight^{31,32}. CPAP machines, on the other hand, usually operate while the patient is sleeping. As such, these machines rarely run for more than a few hours per day. To assess if an extended operation period can have




Figure 3. Illustration of patient-triggered and patient-cycled ventilation. The plots show the measured airway pressure (blue) and flow (red) as a function of time in the event of spontaneous breathing during ventilation (from ~ 16 s). The patient-initiated start of the inhalation and exhalation phase is marked as ‘o’ and ‘x’, respectively.




Figure 4. Plots of the airway pressure, flow, ventilation volume as a function of time for the CPAP machines (a) u1 and (b) u4 (see Table 3). The curves represent the ventilation performance after turning on the ventilator (0 h) and after running for 72 h without a break (72 h). All measurements are performed on an artificial lung. PIP: 20 cmH₂O, Respiratory rate: 20 bpm, I:E ratio: 1:2.

an impact on the ventilation performance, we chose two CPAP machines and measure the ventilation curves after 72 h of operation. During this period, we observed no shutdown of the CPAP machine. Figure 4a,b present the measurements for two CPAP machine models. For the machine in Fig. 4a, we see no changes in the ventilation performance after 72 h. In Fig. 4b, the positive flow reduces after 72 h, which results in a drop of the peak ventilation volume by 8%. On the other hand, both the respiratory rate and the I:E ratio remain unchanged for both ventilators. An evaluation of the baseline for the pressure and the flow curves reveals no shifts over the duration of operation.

Our long-term tests reveal that CARL can operate for an extended period, while the performance of the CPAP machine may drop after a few days. Therefore, it is important to constantly monitor the ventilation curves and, if necessary, replace the CPAP machine to match the patient’s needs.

Discussion

The previous results demonstrate that our module CARL can repurpose CPAP machines to basic ventilators which provide ventilation pressures up to 20 cmH₂O while maintaining a minimum PEEP. Such ventilators may be used on COVID-19 patients with mild symptoms since critically ill patients require higher pressures which common CPAP machines cannot reach³³. To determine the suitable clinical environments, e.g. critical-care or emergency and transport, and applicable clinical cases, an extended testing phase as part of pre-/clinical trials and reviews against international standards or guidelines are required. A crucial part of these examinations are

tests against different lung parameter values such as lung compliance and linear resistance. Here, we tested our ventilator on a lung with lung parameters in the range found in ISO 80601-2-12²⁷. Thus, additional tests are required at a later stage to determine the suitable clinical environment for CARL-based ventilators.

To contribute to the patient's safety and address accidental/unintentional adjustments on the ventilator a set of alarms is essential. In commercial medical-grade ventilators, the set of mandatory alarms depend on the targeted clinical environment and are outlined in international standards such as ISO/TR 21954²⁸. Critical-care ventilators, for example, require additional alarms that monitor the airway pressure, e.g. PEEP or high pressure, the delivered volume and airway obstructions²⁷. So far, CARL has acoustic and visual alarms that monitor the operation of the motor and the connection to the pressure sensors. Protections against high pressures or airway obstructions are currently carried out by a valve unit that is part of CARL's design (see Sect. 6.2). Given that the pressure, flow, and volume are continuously read out in CARL, we can implement in our software all pressure, flow and volume related alarms that are required for the targeted clinical environment.

Since CARL-based ventilators are different to commercial medical-grade ventilators, additional training is necessary for the medical staff. For our ventilator solution, the medical staff must familiarise themselves with the CPAP machine and the CARL module. To reduce the training time required for CARL we use a clear and easy-to-use interface that allows constant patient monitoring and instant access to the ventilation settings, i.e. the respiratory rate and the two I:E ratios. While our basic ventilators require little time to set up and use, they should only be used by a trained staff member with ventilation expertise. This is because the performance of CPAP machines can vary with each model so that only constant monitoring and evaluation of the ventilation curves can lead to a successful patient treatment.

Owing to CARL's modular design, we can develop additional components to include more functionalities without interfering with the ventilator design. One potential component is a module to supply oxygen to the patient at a given oxygen level. This will also imply the addition of an oxygenation measurement device.

Further adjustments to CARL's design could be made to improve the infection control of the module. The design should allow the user to easily clean its surface within a reasonable time frame. In our case, this would primarily concern the components that are in the ventilation pathway. However, since these components are affordable and easy to produce, it may be safer to dispose and replace them instead. Owing to the working principle of CARL, our device could repurpose any continuous positive pressure machine to a basic ventilator. As such, CARL may be the starting point for an open-source ventilator solution. Such decisions, however, require testing the device carefully on animals or patients, which is beyond the scope of this report.

Summary and outlook

The rapid dissemination of COVID-19 has led to a short-term shortage of ventilators worldwide. We believe that CPAP machines repurposed as stripped-down ventilators can help with the crisis in the short term. Our mass-producible solution could be used to vacate medical-grade ventilators for patients in critical conditions. However, in the worst case and after further development and regulatory approval, our solution may be used as a last resort to save the patient's life.

It is important to note that CARL must be rigorously examined and tested before it can be used on humans. This includes stress tests for both hardware and software, performance measurements under clinical conditions and a biocompatibility evaluation of all materials in the ventilation pathway.

Methods

Ventilation specifications for a minimally acceptable ventilator. Our set of ventilation specifications is aimed at COVID-19 patients with mild symptoms as they may not require all functionalities provided by a medical-grade ventilator. A summary of the ventilation variables supported by our system is presented in Table 1. For the definition of the ventilation variables and modes, we use the terminologies and the guidelines provided by Charburn et al.³⁴.

In addition to the ventilation specifications, we also implemented functionalities in CARL's design that ensure the patient's safety during therapy and the safe operation of CARL. These functionalities are summarised in Table 2.

CARL. For the development of our module CARL, we aim for a mass-producible solution that can be manufactured worldwide. To fulfil this criterion, we developed a design that only uses easy-accessible hardware and electronic components. Our current design for CARL is presented in Fig. 5a,b, where the essential components are optimised for mass-production using plastic milling. We also developed and tested a version that can be built with a 3D printer. Subsequent tests show, however, that the results strongly depend on the 3D printer model and, thus, we focus on the plastic-milled version as it yields superior and more consistent results.

CARL serves as an intermediate module that we place in the ventilation pathway between the CPAP machine and the patient (see Fig. 6). The airway pressure that is generated by the CPAP machine in the ventilation pathway is regulated with a rotatable valve: when the valve is open, the airway pressure increases to the peak inspiratory pressure; when it is closed, the airflow stops and the airway pressure drops to zero. A flexible tube is used to bypass the valve and to allow for a continuous minimum airflow to the patient. That way, a minimum airway pressure can be maintained even when the valve is closed. The minimum pressure is determined by the diameter of the bypass channel. In the present case, it is adjusted to maintain a PEEP of at least 5 cmH₂O at 20 cmH₂O. To meet the set respiratory rate and I:E ratio during ventilation, the valve is attached to a computer-controlled motor. The patient receives air through a mask or an endotracheal/tracheostomy tube. Any excess air during the patient's exhalation phase can escape through an exhalation valve that is placed between CARL and the patient.

Ventilation variable	Description	Values
Triggering mechanism	A method to initiate the inspiration phase	Time-triggering, flow-triggering
Cycling mechanism	A method to end the inspiration phase	Time-cycling, flow-cycling
Breath control variable	A parameter that describes the mechanism to assist the patient's breathing	Pressure-control (PC)
Breath sequence	A pattern of mandatory and/or spontaneous breaths	Intermittent mandatory ventilation (IMV)
Targeting Scheme	A method used by the ventilator to achieve a specific ventilation pattern	Set-point (s)
Ventilation Mode	A term to describe the set of ventilation operations based on the selected breath control variable, breath sequence and targeting scheme	PC-IMVs,s
I:E ratio	The ratio of the inspiration (I) and the expiration (E) phase during ventilation	1:1, 1:2
Respiratory rate	The number of breaths per minute (bpm). Here, it is the number of mandatory breaths per minute. The number of spontaneous breaths per minute cannot be lower than the number of mandatory breaths per minute	8–30 bpm
Positive end-expiratory pressure (PEEP)	The airway pressure at the end of the exhalation phase	At least 5 cmH ₂ O
Peak inspiratory pressure	The airway pressure set at the CPAP machine	15–20 cmH ₂ O
Maximum airway pressure	The upper-pressure limit in the patient's airways	30 cmH ₂ O

Table 1. Specifications for a minimally acceptable ventilator to treat COVID-19 patients with mild or moderate symptoms.

Function	Description
Contamination protection	Protection of patient and medical equipment from pathogens
Constant monitoring (settings)	Visual display of airway pressure, tidal volume, and current ventilation settings
Constant monitoring (hardware and software)	Visual and acoustic signals for hardware and software failures during operation

Table 2. Design requirements for CARL to ensure the patient's safety during ventilation.




Figure 5. Illustrations of the module CARL. (a) 3D model of the module CARL. (b) Assembled model of CARL.

We also designed a pop-off valve and a low-pressure valve to contribute to the patient's safety. The former component makes sure that the airway pressure does not exceed 30 cmH₂O, e.g. in the event of a cough. The low-pressure valve guarantees that patients can inhale spontaneously in the event of a hardware or software failure. Additional ventilation parameters, e.g. the FiO₂ value, can be extracted by connecting a patient monitor to the provided connector.

To measure the airway pressure and the flow, we use a flow sensor (No. 281637, Hamilton Medical) that is connected to two implemented pressure sensors (AMS5915-0020-D-B and AMS5915-0050-D-B, Analog Microelectronics GmbH). The flow data is evaluated to determine the ventilation volume and to trigger and to cycle inspiration. As such, we can continuously monitor and evaluate the patient's breathing behaviour during mechanical ventilation.

To comply with safety precautions while in operation, all electronic parts are protected by a professional casting. We use an Arduino Uno and an Arduino Nano to control all electric components in CARL. To implement the ventilation modes in Table 1, we use our own code that is written in C++ and only employs standard libraries.




Figure 6. Schematic of a basic ventilator with a CPAP machine and the module CARL.



Figure 7. Photo of the user interface of CARL. (a) Entire interface with a display of a flow curve. Ventilation parameters are highlighted in orange. (b) Display of the current ventilation parameters and ventilation quantities.

For all timing related functions, e.g. the respiratory rate, we use the standard Arduino function `millis()`, which returns the time that has passed since the program has been started³⁵. After approximately 50 days, the time goes back (rolls over) to zero, which may cause timing issues during ventilation but is accounted for in our code.

Interface/GUI. The use of clear labels is essential for the safe use of CARL by the medical staff. To achieve this, all descriptions use standard terms that are recognised by qualified medical personnel. Figure 7a shows a photo of CARL's user interface. To operate CARL, the user can set the desired I:E ratio and the respiratory rate. The red LED next to the description "Alarm" implies an error during operation. These errors can be defined and implemented into our code. On the display, the user can view the ventilation curves (Fig. 7a shows a flow curve) and the current ventilation parameters and ventilation quantities (Fig. 7b).

Measurement of ventilation quantities. CARL uses accessible pressure sensors to monitor the pressure and the flow that are different to those implemented in medical-grade ventilators. For the sensor used in this study, the accuracy at room temperature is reported as 1 cmH₂O³⁶. Since such sensors are mass-produced, their performance may vary with each product. Because of this, we must validate and calibrate all our measurements with an independent system. Here, we use a system that consists of a pneumotachometer (Model 3700A, Hans Rudolph Inc.) attached to a heater control (Model 3850, Hans Rudolph Inc.) and a DC bridge amplifier (MIO-0501, FMI GmbH). To acquire and evaluate the data from this setup we use the Embria RemLogic Software. For the calibration, we compare both data and adjust for systematic differences so that our data from the sensor matches the one from the external system. A representative result is presented in Fig. 8 which shows that both the pressure and the flow curves are in good agreement after calibration.

To release the excess gas during ventilation, we use an exhalation valve (Whisper Swivel II, Philips Respironics) with a microfilter attached to it. The filter reduces the concentration of released air contaminants in the environment and thus, the overall infection risk for the medical staff. As a patient model, we use an artificial lung (Test Lung 190, Maquet) that has a reported compliance and linear resistance value of $16 \frac{\text{ml}}{\text{cmH}_2\text{O}}$ and $20 \frac{\text{l/s}}{\text{cmH}_2\text{O}}$, respectively³⁷.

In this study, we use five different CPAP machine models which are summarised in Table 3. We refer to them with the term in the column "Reference".




Figure 8. Comparison of measured pressure (blue) and flow (red) data acquired from an external calibrated system (“pnt”) and CARL (“carl”). All measurements are conducted on an artificial lung and the pressure is generated with the CPAP machine u1 (see Table 3). P_{IP} : 20 cmH₂O Respiratory rate: 20 bpm, I:E ratio: 1:2.

Manufacturer	Model	Reference
Löwenstein Medical GmbH	Prisma SOFT	u1
Löwenstein Medical GmbH	Prisma 25 S	u2
Respironics Inc	REMstar C-Flex Int'l	u3
DeVilbiss healthcare	9055SE	u4
Löwenstein Medical GmbH	Phönix 3	u5

Table 3. List of CPAP machine models.

Received: 21 September 2020; Accepted: 28 May 2021

Published online: 09 June 2021

References

- Ranney, M. L., Griffeth, V. & Jha, A. K. Critical supply shortages—the need for ventilators and personal protective equipment during the Covid-19 pandemic. *N. Engl. J. Med.* **382**, e41 (2020).
- McMahon, D. E., Peters, G. A., Ivers, L. C. & Freeman, E. E. Global resource shortages during COVID-19: Bad news for low-income countries. *PLoS Negl. Trop. Dis.* **14**, e0008412 (2020).
- Yang, X. *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. *Lancet Respir. Med.* **8**, 475–481 (2020).
- Haudrebourg, A.-F. *et al.* Respiratory mechanics of COVID-19- versus non-COVID-19-associated acute respiratory distress syndrome. *Am. J. Respir. Crit. Care Med.* **202**, 287–290 (2020).
- Fan, E. *et al.* COVID-19-associated acute respiratory distress syndrome: Is a different approach to management warranted?. *Lancet Respir. Med.* **8**, 816–821 (2020).
- Patrone, D. & Resnik, D. Pandemic ventilator rationing and appeals processes. *Heal. Care Anal.* **19**, 165–179 (2011).
- Guérin, C. & Lévy, P. Easier access to mechanical ventilation worldwide: An urgent need for low income countries, especially in face of the growing COVID-19 crisis. *Eur. Respir. J.* **55**, 2001271 (2020).
- Pearce, J. M. A review of open source ventilators for COVID-19 and future pandemics. *F1000Research* **9**, 218 (2020).
- Mohsenalhusseini, A. *et al.* Design and prototyping of a low-cost portable mechanical ventilator. *J. Med. Dev. Trans. ASME* **4**, 1 (2010).
- Vicente, V. C., Padilla, J. N. & Tanguilig, B. T. T. I. III. Portable automated bag-valve mask with android technology. *Int. J. Adv. Technol. Eng. Explor.* **3**, 28–35 (2016).
- Malya, R. *et al.* A novel augmentation device for ventilation utilizing the bag valve mask in EMS and resource limited settings. *Circulation* **140**, 2 (2019).
- Castro-Camus, E. *et al.* Simple ventilators for emergency use based on Bag-Valve pressing systems: Lessons learned and future steps. *medRxiv* <https://doi.org/10.1101/2020.04.29.20084749> (2020).
- Kwon, A. H., Slocum, A. H., Varellmann, D. & Nabzdyk, C. G. S. Rapidly scalable mechanical ventilator for the COVID-19 pandemic. *Intensive Care Med.* **46**, 1642–1644 (2020).
- Garmendia, O. *et al.* Low-cost, easy-to-build noninvasive pressure support ventilator for under-resourced regions: Open source hardware description, performance and feasibility testing. *Eur. Respir. J.* **55**, 2000846 (2020).
- Abba, A. *et al.* The novel mechanical ventilator Milano for the COVID-19 pandemic. *Phys. Fluids* **33**, 037122 (2021).
- King, W. P. *et al.* Emergency ventilator for COVID-19. *PLoS ONE* **15**, e0244963 (2020).
- Weaver, T. E. & Grunstein, R. R. Adherence to continuous positive airway pressure therapy: The challenge to effective treatment. *Proc. Am. Thorac. Soc.* **5**, 173–178 (2008).
- Somers, M. L., Peterson, E., Sharma, S. & Yaremchuk, K. Continuous positive airway pressure adherence for obstructive sleep apnea. *ISRN Otolaryngol.* **2011**, 1–7 (2011).

19. Rotenberg, B. W., Murariu, D. & Pang, K. P. Trends in CPAP adherence over twenty years of data collection: A flattened curve. *J. Otolaryngol. Head Neck Surg.* **45**, 43 (2016).
20. MHRA. *Rapidly manufactured ventilator system specification*. Medicines and Healthcare Products Regulatory Agency (2020).
21. Marini, J. J. & Gattinoni, L. Management of COVID-19 respiratory distress. *JAMA* **323**, 2329 (2020).
22. Jamil, S. *et al.* Diagnosis and management of COVID-19 disease. *Am. J. Respir. Crit. Care Med.* **201**, P19–P20 (2020).
23. Alhazzani, W. *et al.* Surviving sepsis campaign: Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Med.* **46**, 854–887 (2020).
24. Tobin, M. J. *Principles And Practice of Mechanical Ventilation* 3rd edn. (McGraw-Hill Education, 2012).
25. Vieira, L., Silva, V., Guimarães, M. E., Hussey, G. & Castro, J. Safety and effectiveness of ventilator hyperinflation, associated or not to manual abdominal compression, in critically ill patients under mechanical ventilation. In *Physiotherapists PA2552* (European Respiratory Society, 2017). doi:<https://doi.org/10.1183/1393003.congress-2017.PA2552>.
26. Thomas, P. *et al.* Physiotherapy management for COVID-19 in the acute hospital setting: Clinical practice recommendations. *J. Physiother.* **66**, 73–82 (2020).
27. ISO 80601-2-12:2020 - *Medical electrical equipment — Part 2-12: Particular requirements for basic safety and essential performance of critical care ventilators*. (2020).
28. ISO/TR 21954:2018 - *Guidance on the selection of the appropriate means of ventilation based on the intended patient, use environment, and operator*. (2018).
29. Mauri, T., Cambiaghi, B., Spinelli, E., Langer, T. & Grasselli, G. Spontaneous breathing: A double-edged sword to handle with care. *Ann. Transl. Med.* **5**, 292–292 (2017).
30. Yoshida, T., Fujino, Y., Amato, M. B. P. & Kavanagh, B. P. Spontaneous Breathing during Mechanical Ventilation. Risks, Mechanisms, and Management. *Am. J. Respir. Crit. Care Med.* **195**, 985–992 (2017).
31. Carter, C., Osborn, M., Agagah, G., Aedy, H. & Notter, J. COVID-19 disease: invasive ventilation. *Clin. Integr. Care* **1**, 100004 (2020).
32. Karagiannidis, C. *et al.* Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. *Lancet Respir. Med.* **8**, 853–862 (2020).
33. Grasselli, G. *et al.* Mechanical ventilation parameters in critically ill COVID-19 patients: A scoping review. *Crit. Care* **25**, 115 (2021).
34. Chatburn, R. L., El-Khatib, M. & Mireles-Cabodevila, E. A taxonomy for mechanical ventilation: 10 fundamental maxims. *Respir. Care* **59**, 1747–1763 (2014).
35. Arduino Language Reference. <https://www.arduino.cc/reference/en/language/functions/time/millis/>.
36. Data Sheet for AMS 5915. (2019).
37. Duchateau, P. & Guérin, C. Tidal volume delivery from ICU Ventilators in BTPS condition. A bench study. *Respir. Care* <https://doi.org/10.4187/respca.01915> (2012).

Acknowledgements

We acknowledge financial support from the Minister for Higher Education, Research and the Arts of the German State of Hessen and from the Sparkasse Marburg-Biedenkopf. We also thank Dr. Tobias Breuer, Anna Lena Isenberg, Sven Heuer, Philipp Bergen, Lea Eller, Meral Kara, Fritz Winter Eisengießerei GmbH & Co. KG and Conrad Electronic for their support throughout this research.

Author contributions

G.K., K.K. proposed the concept for CARL; E.C.C. proposed the study supported by M.K., M.K. coordinated the workgroup; C.B., J.H., P.L., A.P., D.G. contributed to the development of the software framework; G.K., C.B., J.H., C.S., C.So. contributed to the implementation of the electronic components; P.M., N.H., B.L.T., H.B., G.K., K.K. contributed to the development of the CARL prototype; K.K., J.N., J.H. performed and evaluated all measurements; R.H., P.W., T.W., B.B. provided medical expertise; K.K., J.H., P.L., C.B., J.N. contributed to the documentation; J.N., G.S., M.K. provided coordination between the medical, mechanical/software developers and test experts; The manuscript was written by J.N., E.C.C. All authors reviewed the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to J.N.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021